tiprankstipranks
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
PremiumPress ReleasesRelay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
2M ago
Relay Therapeutics price target raised to $30 from $25 at Stifel
PremiumThe Fly
Relay Therapeutics price target raised to $30 from $25 at Stifel
2M ago
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
PremiumPress Releases
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
2M ago
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress ReleasesRelay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
3M ago
Relay Therapeutics price target lowered by $2 at H.C. Wainwright, here’s why
PremiumThe Fly
Relay Therapeutics price target lowered by $2 at H.C. Wainwright, here’s why
4M ago
Relay Therapeutics price target lowered to $19 from $33 at H.C. Wainwright
PremiumThe Fly
Relay Therapeutics price target lowered to $19 from $33 at H.C. Wainwright
5M ago
Relay Therapeutics price target raised to $33 from $30 at H.C. Wainwright
PremiumThe FlyRelay Therapeutics price target raised to $33 from $30 at H.C. Wainwright
6M ago
Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors
PremiumThe Fly
Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors
6M ago
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
PremiumPress Releases
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100